Novome gets $43.5M boost for its engineered microbiome therapies
Novome Biotechnologies — a biotech that CEO Blake Wise says is only company to pursue engineered cell therapy with microbes for the treatment of chronic diseases — raised $43.5 million in Series B funds. The biotech will use the money to advance clinical testing for its lead drug candidate, which seeks to decrease patients' urinary oxalate, as well as advance its pipeline of preclinical genetically engineered microbes.